Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.

التفاصيل البيبلوغرافية
العنوان:	Natural Disease Course of Ulcerative Colitis During the First Five Years of Follow-up in a European Population-based Inception Cohort-An Epi-IBD Study.
المؤلفون:	Burisch J; Department of Gastroenterology, Nordsjællands Hospital, University of Copenhagen, Frederikssund, Denmark., Katsanos KH; Department of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece., Christodoulou DK; Department of Gastroenterology, University Hospital of Ioannina, Ioannina, Greece., Barros L; Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal., Magro F; Department of Gastroenterology, Centro Hospitalar de São João EPE, Porto, Portugal.; Department of Biomedicine, Institute of Pharmacology, Faculty of Medicine of Porto University, Porto, Portugal., Pedersen N; Gastroenterology Department, Slagelse Hospital, Slagelse, Denmark., Kjeldsen J; Gastroenterology Department, Odense University Hospital, Odense, Denmark., Vegh Z; First Department of Medicine, Semmelweis University, Budapest, Hungary., Lakatos PL; First Department of Medicine, Semmelweis University, Budapest, Hungary.; Division of Gastroenterology, McGill University Health Center, Montreal, QC, Canada., Eriksson C; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Halfvarson J; Department of Gastroenterology, Faculty of Medicine and Health, Örebro University, Örebro, Sweden., Fumery M; Gastroenterology Unit, Epimad Registry, CHU Amiens Sud, Amiens University Hospital, Amiens, France., Gower-Rousseau C; Public Health, Epidemiology and Economic Health, Registre Epimad, Lille University and Hospital, Lille, France.; Lille Inflammation Research International Center LIRIC, Lille University, Lille, France., Brinar M; Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia., Cukovic-Cavka S; Division of Gastroenterology and Hepatology, University Hospital Center Zagreb, Zagreb, Croatia.; School of Medicine, University of Zagreb, Zagreb, Croatia., Nikulina I; Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation., Belousova E; Department of Gastroenterology, Moscow Regional Research Clinical Institute, Moscow, Russian Federation., Myers S; IBD Unit, Hull and East Yorkshire NHS Trust, Hull, UK., Sebastian S; IBD Unit, Hull and East Yorkshire NHS Trust, Hull, UK., Kiudelis G; Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania., Kupcinskas L; Institute for Digestive Research, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania.; Department of Gastroenterology, Medical Academy, Lithuanian University of Health Sciences, Kaunas, Lithuania., Schwartz D; Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel., Odes S; Department of Gastroenterology and Hepatology, Soroka Medical Center and Ben Gurion University of the Negev, Beer Sheva, Israel., Kaimakliotis IP; American Gastroenterology Center, Nicosia, Cyprus., Valpiani D; U.O. Gastroenterologia ed Endoscopia digestiva, Hospital Morgagni Pierantoni, Forlì, Italy., D'Incà R; Department of Surgical, Oncological and Gastroenterological Sciences, Azienda, University of Padua, Padova, Italy., Salupere R; Division of Gastroenterology, Tartu University Hospital, University of Tartu, Tartu, Estonia., Chetcuti Zammit S; Division of Gastroenterology, Mater Dei Hospital, Msida, Malta., Ellul P; Division of Gastroenterology, Mater Dei Hospital, Msida, Malta., Duricova D; IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic., Bortlik M; IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic.; Institute of Pharmacology, First Faculty of Medicine, Charles University in Prague, Prague, Czech Republic., Goldis A; Clinic of Gastroenterology, University of Medicine 'Victor Babes', Timisoara, Romania., Kievit HAL; Department of Medicine, Herning Central Hospital, Herning, Denmark., Toca A; Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova., Turcan S; Department of Gastroenterology, State University of Medicine and Pharmacy of the Republic of Moldova, Chisinau, Republic of Moldova., Midjord J; Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands., Nielsen KR; Medical Department, National Hospital of the Faroe Islands, Torshavn, Faroe Islands., Andersen KW; Medical Department, Regional Hospital of Viborg, Viborg, Denmark., Andersen V; Medical Department, Regional Hospital of Viborg, Viborg, Denmark.; Focused Research Unit for Molecular Diagnostic and Clinical Research [MOK], IRS-Center Sonderjylland, Hospital of Southern Jutland, Aabenraa, Denmark.; Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark., Misra R; IBD Department, St Mark's Hospital, London, UK., Arebi N; IBD Department, St Mark's Hospital, London, UK., Oksanen P; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.; University of Tampere, Tampere, Finland., Collin P; Department of Gastroenterology and Alimentary Tract Surgery, Tampere University Hospital, Tampere, Finland.; University of Tampere, Tampere, Finland., de Castro L; Department of Gastroenterology. Hospital Alvaro Cunqueiro, Instituto Investigación Sanitaria Galicia Sur, EOXI de Vigo, Vigo, Spain., Hernandez V; Department of Gastroenterology. Hospital Alvaro Cunqueiro, Instituto Investigación Sanitaria Galicia Sur, EOXI de Vigo, Vigo, Spain., Langholz E; Department of Gastroenterology, Herlev and Gentofte Hospital, University of Copenhagen, Copenhagen, Denmark., Munkholm P; Department of Gastroenterology, Nordsjællands Hospital, University of Copenhagen, Frederikssund, Denmark.
مؤلفون مشاركون:	Epi-IBD Group
المصدر:	Journal of Crohn's & colitis [J Crohns Colitis] 2019 Feb 01; Vol. 13 (2), pp. 198-208.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN: 1876-4479 (Electronic) Linking ISSN: 18739946 NLM ISO Abbreviation: J Crohns Colitis Subsets: MEDLINE
أسماء مطبوعة:	Publication: 2015- : Oxford : Oxford University Press Original Publication: Amsterdam : Elsevier Science
مواضيع طبية MeSH:	Colitis, Ulcerative/*pathology, Adult ; Colectomy/statistics & numerical data ; Colitis, Ulcerative/therapy ; Disease Progression ; Europe ; Female ; Follow-Up Studies ; Gastrointestinal Agents/therapeutic use ; Hospitalization/statistics & numerical data ; Humans ; Immunologic Factors/therapeutic use ; Male ; Middle Aged ; Prospective Studies
مستخلص:	Background and Aims: Few population-based cohort studies have assessed the disease course of ulcerative colitis [UC] in the era of biological therapy and widespread use of immunomodulators. The aim of this study was to assess the 5-year outcome and disease course of patients with UC in the Epi-IBD cohort. Methods: In a prospective, population-based inception cohort of unselected patients with UC, patients were followed up from the time of their diagnosis, which included the collection of their clinical data, demographics, disease activity, medical therapy, and rates of surgery, cancers, and deaths. Associations between outcomes and multiple covariates were analysed by Cox regression analysis. Results: A total of 717 patients were included in the study. During follow-up, 43 [6%] patients underwent a colectomy and 163 [23%] patients were hospitalised. Of patients with limited colitis [distal to the left flexure], 90 [21%] progressed to extensive colitis. In addition, 92 [27%] patients with extensive colitis experienced a regression in disease extent, which was associated with a reduced risk of hospitalisation (hazard ratio [HR]: 0.5 95% CI: 0.3-0.8]. Overall, patients were treated similarly in both geographical regions; 80 [11%] patients needed biological therapy and 210 [29%] patients received immunomodulators. Treatment with immunomodulators was found to reduce the risk of hospitalisation [HR: 0.5 95% CI: 0.3-0.8]. Conclusions: Although patients in this population-based cohort were treated more aggressively with immunomodulators and biological therapy than in cohorts from the previous two decades, their disease outcomes, including colectomy rates, were no different. However, treatment with immunomodulators was found to reduce the risk of hospitalisation.
المشرفين على المادة:	0 (Gastrointestinal Agents) 0 (Immunologic Factors)
تواريخ الأحداث:	Date Created: 20181006 Date Completed: 20190528 Latest Revision: 20220331
رمز التحديث:	20231215
DOI:	10.1093/ecco-jcc/jjy154
PMID:	30289522
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1876-4479
DOI:	10.1093/ecco-jcc/jjy154